In my clinical practice, this is one of the most frequent things that I am asked to address -- whether it is dual antiplatelet therapy, stopping antiplatelet therapy in general, or stopping anticoagulants and adopting NOACs. It has been a challenge, but we have pretty good data to help guide decisions about NOACs, and this has been extensively covered.
But the issue about NOAC transitions is that we don't have a lot of data. It is uncharted territory. Making sense of NOAC transitions is something that I am trying to address for myself and sharing here in this blog to you as the "co-pupil" or "co-traveler" in this difficult area.